LYPD3

LYPD3

LYPD3 Molekülinformation

Molecule Name
Ly6/PLAUR domain-containing protein 3
Molekülalias
LYPD3,MIG-C4,C4.4A
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,Matrigel-Induced Gene C4 Protein,LY6/PLAUR Domain Containing 3
Molekülhintergrund
Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.

LYPD3 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Lupartumab amadotinBAY-1129980Phase 1 ClinicalBayer AG
Neoplasms
Details